T1	Participants 84 121	patients with decompensated cirrhosis
T2	Participants 142 272	Patients with cirrhosis undergoing selective intestinal decontamination with norfloxacin show a reduction in serum cytokine levels
T3	Participants 367 450	Thirty-one patients with cirrhosis receiving norfloxacin (400 mg/day) were included
T4	Participants 635 749	Single doses of norfloxacin and trimethoprim/sulfamethoxazole were administered to 13 and 5 patients, respectively
